ARTICANZ - Beta (ver 0.91)
Annotated Registry of Trials in Cancer, Australia and New Zealand Ed.
- Results - location/NSW/2139-Concord-Concord-Repatriation-General-Hospital
Home
By cancer type
By drug class
By site
Data
FAQ
About
⚠
ARTICANZ provides informational content about cancer drug trials in Australia/NZ that is updated weekly but may not be completely accurate, and should not replace medical advice from qualified healthcare professionals. The platform is intended to be useful, providing information "as is" without warranties. Non-medical users must always consult healthcare providers for all clinical decisions.
Search results
27
trial(s) found.
NCT07678593
Advanced
Phase 1 / Phase 2
Not yet recruiting
A Multi-center, Open-label Phase Ib/II Study Exploring the Safety/Tolerability, Pharmacokinetics, and Efficacy of GFH276 in Combination With Cetuximab or Chemotherapy in the Treatment of Patients With Advanced Solid Tumors and Pancreatic Ductal Adenocarcinoma (PDAC) Harboring RAS Mutation (
GFH276X0201
)
anti-EGFR monoclonal antibody
pan-RAS inhibitor,tricomplex inhibitor
Cancer
Pancreatic adenocarcinoma
Solid tumour
NSW
2109 - North Ryde - Macquarie University Hospital
2139 - Concord - Concord Repatriation General Hospital
VIC
3066 - Epping - Northern Hospital
3168 - Clayton - Monash Medical Centre
3199 - Frankston - PASO Medical
SA
5011 - Woodville South - The Queen Elizabeth Hospital
NCT07023627
Advanced
Phase 2
Recruiting
A Phase 2, Single-Arm Study of INCB123667 in Participants With Platinum-Resistant Ovarian Cancer With Cyclin E1 Overexpression (MAESTRA 1) (
MAESTRA-1
)
CDK2 inhibitor
Ovarian cancer
NSW
2139 - Concord - Concord Repatriation General Hospital
2148 - Blacktown - Blacktown Hospital, Blacktown Cancer and Haematology Centre
SA
5000 - Adelaide - Cancer Research SA
5065 - Toorak Gardens - Burnside War Memorial Hospital
TAS
7000 - Hobart - Royal Hobart Hospital
NCT06914128
Advanced
Phase 1 / Phase 2
Recruiting
A First-in-human Study to Evaluate the Safety, Tolerability and Pharmacokinetics, Pharmacodynamics and Preliminary Clinical Activity of BAY 3713372, a Novel 2nd Generation PRMT5 Inhibitor, in Participants With MTAP-deleted Solid Tumors.
PRMT5 inhibitor
NOT Glioblastoma
NOT High-grade glioma
NOT Pancreatic adenocarcinoma
Non-small cell lung cancer
Pancreatic adenocarcinoma
NSW
2050 - Camperdown - Chris O'Brien Lifehouse
2139 - Concord - Concord Repatriation General Hospital
2298 - Waratah - Calvary Mater Newcastle Medical Oncology
VIC
3066 - Epping - Northern Hospital (SUSPENDED)
NCT06750094
Advanced
Phase 3
Recruiting
A Randomized, Open-label Phase 3 Study of Amivantamab + FOLFIRI Versus Cetuximab/Bevacizumab + FOLFIRI in Participants With KRAS/NRAS and BRAF Wild-type Recurrent, Unresectable or Metastatic Colorectal Cancer Who Have Received Prior Chemotherapy (
OrigAMI-3
)
anti-EGFR monoclonal antibody
anti-VEGF monoclonal antibody
bispecific cMET/EGFR antibody
Colorectal adenocarcinoma
NSW
2139 - Concord - Concord Repatriation General Hospital
VIC
3021 - St Albans - Western Health - Sunshine Hospital
3084 - Heidelberg - Warringal Private Hospital
SA
5011 - Woodville South - The Queen Elizabeth Hospital
NCT06651229
Advanced
Phase 1
Recruiting
A Phase 1, First-in-Human, Dose Escalation Study of JNJ-90189892 for Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Neoplasms (
90189892AML1001
)
unknown drug class
Cancer
Leukaemia
NSW
2139 - Concord - Concord Repatriation General Hospital
VIC
3000 - Melbourne - Peter MacCallum Cancer Centre
WA
6009 - Nedlands - Sir Charles Gairdner Hospital - WA Cancer Centre
NCT06532006
Advanced
Phase 3
Recruiting
A Randomized, Double-blinded, Multicenter, Phase Ⅲ Clinical Study of HLX22 (Recombinant Humanized Anti-HER2 Monoclonal Antibody Injection) in Combination With Trastuzumab and Chemotherapy (XELOX) Versus Trastuzumab and Chemotherapy (XELOX) With or Without Pembrolizumab for the First Line Treatment of Locally Advanced or Metastatic Gastroesophageal Junction and Gastric Cancer (
HLX22-GC-301
)
anti-ERBB2 monoclonal antibody
anti-PD-1 monoclonal antibody
Gastric cancer
Gastroesophageal junction adenocarcinoma
HER2-positive gastric cancer
NSW
2109 - North Ryde - Macquarie University Hospital
2139 - Concord - Concord Repatriation General Hospital
2250 - Gosford - Central Coast Cancer Centre, Gosford Hospital
2560 - Campbelltown - GenesisCare Campbelltown
VIC
3065 - Fitzroy - St Vincent's Hospital Melbourne
3199 - Frankston - Peninsula Health Frankston Hospital
QLD
4556 - Buderim - Sunshine Coast Haematology and Oncology Clinic
NCT06467357
Advanced
Phase 3
Recruiting
DESTINY-Biliary Tract Cancer-01: A Phase 3 Study of Trastuzumab Deruxtecan (T-DXd) and Rilvegostomig Versus Standard-of-Care Gemcitabine, Cisplatin, and Durvalumab for First Line Locally Advanced or Metastatic HER2-expressing Biliary Tract Cancer (
DESTINY-BTC01
)
anti-ERBB2 antibody-drug conjugate,topoisomerase inhibitor 1-payload
anti-PD-L1 monoclonal antibody
antimetabolite
bispecific PD-1/TIGIT antibody
platinum-based antineoplastic agent
Biliary tract cancer
NSW
2139 - Concord - Concord Repatriation General Hospital
VIC
3168 - Clayton - Monash Medical Centre
QLD
4032 - Chermside - The Prince Charles Hospital
WA
6009 - Nedlands - Sir Charles Gairdner Hospital - WA Cancer Centre
NCT06452277
Advanced
Phase 3
Recruiting
A Phase 3 Open-label, Randomized, Active-controlled, Multicenter Trial to Evaluate the Efficacy and Safety of Orally Administered BAY 2927088 Compared With Standard of Care as a First-line Therapy in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC) With HER2-activating Mutations (
SOHO-02
)
EGFR/ERBB2 inhibitor,mutant-selective,non-covalent
Non-small cell lung cancer
NSW
2139 - Concord - Concord Repatriation General Hospital
2148 - Blacktown - Blacktown Hospital, Blacktown Cancer and Haematology Centre
2298 - Waratah - Calvary Mater Newcastle Medical Oncology
ACT
2605 - Garran - The Canberra Hospital
VIC
3084 - Heidelberg - Austin Hospital Olivia Newton-John Cancer Centre
QLD
4556 - Buderim - Sunshine Coast Haematology and Oncology Clinic
4350 - Toowoomba - Toowoomba Hospital (WITHDRAWN)
NCT06120283
Advanced
Phase 1
Recruiting
A Phase 1a/1b Study Investigating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Antitumor Activity of the CDK4 Inhibitor BGB-43395, Alone or as Part of Combination Therapies in Patients With Metastatic HR+/HER2- Breast Cancer and Other Advanced Solid Tumors (
BGB-43395-101
)
CDK4 selective inhibitor
Breast cancer
Cancer
HER2-negative breast cancer
HR-positive breast cancer
Non-small cell lung cancer
Solid tumour
NSW
2109 - North Ryde - Macquarie University Hospital
2139 - Concord - Concord Repatriation General Hospital
2148 - Blacktown - Blacktown Hospital, Blacktown Cancer and Haematology Centre
2576 - Bowral - Southern Highlands Private Hospital
VIC
3000 - Melbourne - Peter MacCallum Cancer Centre
3084 - Heidelberg - Austin Hospital Olivia Newton-John Cancer Centre
QLD
4814 - Douglas - Townsville Cancer Centre - The Townsville Hospital
SA
5000 - South Australia - GenesisCare St Andrews Hospital
NZ
NZ.1023 - Grafton - Auckland City Hospital - Cancer & Blood Research
NZ.8011 - Christchurch - Canterbury District Health Board - Christchurch Hospital Cancer Centre
NCT05914116
Advanced
Phase 1 / Phase 2
Recruiting
A Phase 1/2a, Multicenter, Open-Label, First in Human Study to Assess the Safety, Tolerability, Pharmacokinetics, and Preliminary Antitumor Activity of DB-1311 in Subjects With Advanced/Metastatic Solid Tumors (
DB-1311-O-1001
)
anti-B7H3 antibody-drug conjugate
anti-B7H3 antibody-drug conjugate,topoisomerase inhibitor 1-payload
Solid tumour
NSW
2031 - Randwick - Scientia Clinical Research Ltd
2050 - Camperdown - Chris O'Brien Lifehouse
2109 - North Ryde - Macquarie University Hospital
2139 - Concord - Concord Repatriation General Hospital
2148 - Blacktown - Blacktown Hospital, Blacktown Cancer and Haematology Centre
2228 - Miranda - Southside Cancer Care Centre
2298 - Waratah - Calvary Mater Newcastle Medical Oncology
2305 - New Lambton Heights - John Hunter Children's Hospital
QLD
4102 - Woolloongabba - Princess Alexandra Hospital
4224 - Tugun - Genesis Care Tugun - John Flynn Private Hospital
4575 - Birtinya - Sunshine Coast University Hospital
WA
6009 - Nedlands - Sir Charles Gairdner Hospital - WA Cancer Centre
NCT05872295
Advanced
Phase 1
Recruiting
A Phase 1 Dose Escalation Trial to Determine the Safety, Tolerance, Maximum Tolerated Dose, and Preliminary Antineoplastic Activity of IKS014, a HER2-Targeting Antibody Drug Conjugate (ADC), in Participants With Advanced HER2+ Solid Tumors (
IKS014-01
)
anti-ERBB2 antibody-drug conjugate,MMAF-payload
Breast cancer
Gastric cancer
Gastroesophageal junction adenocarcinoma
Solid tumour
NSW
2109 - North Ryde - Macquarie University Hospital
2139 - Concord - Concord Repatriation General Hospital
2145 - Westmead - The Crown Princess Mary Cancer Centre - Westmead Hospital
VIC
3004 - Melbourne, Southbank - Alfred Health
3199 - Frankston - Peninsula Health Frankston Hospital
WA
6009 - Nedlands - Linear Clinical Research
NZ
NZ.1023 - Grafton - Auckland City Hospital - Cancer & Blood Research
NCT05789082
Advanced
Phase 1 / Phase 2
Recruiting
A Phase Ib/II, Open-Label, Multicenter Study Evaluating the Safety, Activity, and Pharmacokinetics of Divarasib as a Single Agent or in Combination With Other Anti-Cancer Therapies in Patients With Previously Untreated Advanced Or Metastatic Non-Small Cell Lung Cancer With a KRAS G12C Mutation (
KRAScendo-170
)
KRAS G12C inhibitor,OFF-state inhibitor
Non-small cell lung cancer
NSW
2139 - Concord - Concord Repatriation General Hospital (COMPLETED)
VIC
3000 - Melbourne - Peter MacCallum Cancer Centre
3004 - Melbourne, Southbank - Alfred Health
NCT05774951
Curative
Phase 3
Recruiting
CAMBRIA-1
: A Phase III, Open-Label, Randomised Study to Assess the Efficacy and Safety of Extended Therapy With Camizestrant (AZD9833, a Next Generation, Oral Selective Estrogen Receptor Degrader) Versus Standard Endocrine Therapy (Aromatase Inhibitor or Tamoxifen) in Patients With ER+/HER2- Early Breast Cancer and an Intermediate or High Risk of Recurrence Who Have Completed Definitive Locoregional Therapy and at Least 2 Years of Standard Adjuvant Endocrine-Based Therapy Without Disease Recurrence
selective estrogen receptor degrader
selective estrogen receptor modulator
Breast cancer
NSW
2031 - Randwick - Prince of Wales Hospital
2139 - Concord - Concord Repatriation General Hospital
2298 - Waratah - Calvary Mater Newcastle Medical Oncology
2485 - Tweed Heads - The Tweed Hospital (WITHDRAWN)
VIC
3355 - Wendouree - Ballarat Oncology & Haematology Clinical Trials Unit
QLD
4575 - Birtinya - Sunshine Coast University Hospital
WA
6009 - Nedlands - Sir Charles Gairdner Hospital - WA Cancer Centre (WITHDRAWN)
NCT05696626
Advanced
Phase 3
Recruiting
An Open Label, Randomized, Multicenter Study Comparing the Efficacy and Safety of the Combination of Lasofoxifene and Abemaciclib to the Combination of Fulvestrant and Abemaciclib for the Treatment of Pre- and Postmenopausal Women and Men With Locally Advanced or Metastatic ER+/HER2- Breast Cancer With an ESR1 Mutation (
ELAINEIII
)
CDK4/6 inhibitor
selective estrogen receptor degrader
selective estrogen receptor modulator
Breast cancer
NSW
2139 - Concord - Concord Repatriation General Hospital
2148 - Blacktown - Blacktown Hospital, Blacktown Cancer and Haematology Centre
QLD
4101 - South Brisbane - Mater Hospital Brisbane / ICON Cancer Centre
NCT04771130
Advanced
Phase 1 / Phase 2
Recruiting
A Phase 1b/2, Open-Label, Dose Finding, and Expansion Study of the Bcl-2 Inhibitor BGB-11417 in Patients With Myeloid Malignancies (
BGB-11417-103
)
Bcl2 inhibitor
Acute myeloid leukaemia
Myelodysplastic syndrome
Myelodysplastic/Myeloproliferative disease
NSW
2139 - Concord - Concord Repatriation General Hospital
2217 - Kogarah - St George Hospital
2800 - Orange - Orange Hospital-Cancer Centre Clinical Trials Unit
VIC
3004 - Melbourne, Southbank - Alfred Health
3065 - Fitzroy - St Vincent's Hospital Melbourne
3084 - Heidelberg - Austin Hospital Olivia Newton-John Cancer Centre
3168 - Clayton - Monash Medical Centre
QLD
4215 - Southport - Gold Coast University Hospital
WA
6009 - Nedlands - One Clinical Research
6009 - Nedlands - Sir Charles Gairdner Hospital - WA Cancer Centre
6150 - Murdoch - Fiona Stanley Hospital
NZ
NZ.0622 - Takapuna - North Shore Hospital
NZ.6021 - Wellington - Capital & Coast District Health Board - Wellington Hospital
NCT02582697
Advanced
Phase 3
Recruiting
Phase 3 Accelerated BEP: A Randomised Phase 3 Trial of Accelerated Versus Standard BEP Chemotherapy for Patients With Intermediate and Poor-risk Metastatic Germ Cell Tumours (
P3BEP
)
Bleomycin
Cisplatin
Etoposide
Filgrastim
Pegfilgrastim
antineoplastic antibiotic
cancer therapy
cytotoxic chemotherapy
platinum-based antineoplastic agent
topoisomerase inhibitor
Germ cell tumour
NSW
2031 - Randwick - Prince of Wales Hospital
2050 - Camperdown - Chris O'Brien Lifehouse
2065 - St Leonards - Northern Sydney Cancer Centre, Royal North Shore Hospital
2076 - Wahroonga - Sydney Adventist Hospital
2109 - North Ryde - Macquarie University Hospital
2139 - Concord - Concord Repatriation General Hospital
2298 - Waratah - Calvary Mater Newcastle Medical Oncology
2485 - Tweed Heads - The Tweed Hospital
2747 - Kingswood - Nepean Hospital - Nepean Cancer Care Centre
2145 - Westmead - The Crown Princess Mary Cancer Centre - Westmead Hospital (WITHDRAWN)
VIC
3002 - Melbourne - Peter MacCallum Cancer Centre, East Melbourne campus
3084 - Heidelberg - Austin Hospital Olivia Newton-John Cancer Centre
3128 - Box Hill - Box Hill Hospital - Eastern Health
3690 - Wodonga - Border Medical Oncology at Wodonga Regional Cancer Centre
3021 - St Albans - Western Health - Sunshine Hospital (WITHDRAWN)
QLD
4006 - Herston - The Royal Brisbane and Women's Hospital Cancer Centre
4101 - South Brisbane - Queensland Children's Hospital
4102 - Woolloongabba - Princess Alexandra Hospital
SA
5000 - Adelaide - Royal Adelaide Hospital - Adelaide Cancer Centre
5042 - Bedford Park - Flinders Medical Centre
WA
6150 - Murdoch - Fiona Stanley Hospital
TAS
7000 - Hobart - Royal Hobart Hospital
NZ
NZ.1023 - Grafton - Auckland City Hospital - Cancer & Blood Research
NZ.1023 - Grafton - Starship Children's Hospital
NZ.4442 - Roslyn - Palmerston North Hospital Cancer Centre - Palmerston North Hospital
NZ.8011 - Christchurch - Canterbury District Health Board - Christchurch Hospital Cancer Centre
NZ.9016 - Dunedin - Dunedin Hospital (WITHDRAWN)
ACTRN12625001239459
Advanced
Phase 3
Not yet recruiting
Randomised Double-Blind Placebo-Controlled Clinical Trial of Effect of Transdermal Testosterone on Serum Testosterone in Prolonged GnRH Agonist-induced Hypogonadism: A Pilot Study (
NIL
)
placebo
Prostate cancer
NSW
2139 - Concord - Concord Repatriation General Hospital
ACTRN12625000824460
Haem
Phase 1 / Phase 2
Not yet recruiting
AMLM26/T9 - INTERCEPT (Investigating Novel Therapy to Target Early Relapse and Clonal Evolution as Pre-emptive Therapy in AML)): A Multi-arm, Precision-based, Recursive, Platform Trial- PHI-101 (
AMLM26-T9
)
Acute myeloid leukaemia
NSW
2050 - Camperdown - Chris O'Brien Lifehouse
2065 - St Leonards - Northern Sydney Cancer Centre, Royal North Shore Hospital
2139 - Concord - Concord Repatriation General Hospital
2145 - Westmead - The Crown Princess Mary Cancer Centre - Westmead Hospital
2298 - Waratah - Calvary Mater Newcastle Medical Oncology
VIC
3000 - Melbourne - Peter MacCallum Cancer Centre
3053 - Parkville - The Royal Women's Hospital and Institute of Maternal and Child Health
3168 - Clayton - Monash Medical Centre
3220 - Geelong - Andrew Love Cancer Centre, University Hospital Geelong
QLD
4006 - Herston - The Royal Brisbane and Women's Hospital Cancer Centre
4102 - Woolloongabba - Princess Alexandra Hospital
4215 - Southport - Gold Coast University Hospital
SA
5000 - Adelaide - Royal Adelaide Hospital - Adelaide Cancer Centre
WA
6009 - Nedlands - Sir Charles Gairdner Hospital - WA Cancer Centre
6150 - Murdoch - Fiona Stanley Hospital
ACTRN12625000438459
Haem
Phase 2
Recruiting
A Centralized Platform study for Functional High Risk Multiple Myeloma: Domain 1 - Talquetamab and Teclistamab (
ZEPFHR-MM-Domain-1
)
bispecific T-cell engager,BCMA-targeting
bispecific T-cell engager,GPRC5D-targeting
Multiple myeloma
NSW
2050 - Camperdown - Chris O'Brien Lifehouse
2139 - Concord - Concord Repatriation General Hospital
VIC
3004 - Melbourne, Southbank - Alfred Health
3084 - Heidelberg - Austin Hospital Olivia Newton-John Cancer Centre
3128 - Box Hill - Box Hill Hospital - Eastern Health
3220 - Geelong - Andrew Love Cancer Centre, University Hospital Geelong
QLD
4006 - Herston - The Royal Brisbane and Women's Hospital Cancer Centre
4102 - Woolloongabba - Princess Alexandra Hospital
WA
6009 - Nedlands - Sir Charles Gairdner Hospital - WA Cancer Centre
ACTRN12625000429459
Haem
Phase 2
Recruiting
A Centralized Platform study for Functional High Risk Multiple Myeloma - Master Protocol (
ZEPFHR-MM
)
Multiple myeloma
NSW
2050 - Camperdown - Chris O'Brien Lifehouse
2139 - Concord - Concord Repatriation General Hospital
2170 - Liverpool - Liverpool Hospital
2298 - Waratah - Calvary Mater Newcastle Medical Oncology
VIC
3004 - Melbourne, Southbank - Alfred Health
3128 - Box Hill - Box Hill Hospital - Eastern Health
3220 - Geelong - Andrew Love Cancer Centre, University Hospital Geelong
QLD
4102 - Woolloongabba - Princess Alexandra Hospital
ACTRN12624000288527
Advanced
Phase 3
Recruiting
Efficacy of intraperitoneal bevacizumab for decreasing or delaying re-accumulation of recurrent malignant ascites in chemotherapy resistant solid tumours: a randomised trial (
REZOLV3R
)
anti-VEGF monoclonal antibody
Solid tumour
NSW
2060 - North Sydney - Mater Hospital
2139 - Concord - Concord Repatriation General Hospital
VIC
3002 - East Melbourne - Epworth Freemasons
3677 - Wangaratta - Northeast Health Wangaratta
SA
5042 - Bedford Park - Flinders Medical Centre
ACTRN12624000141549
Haem
Phase 1 / Phase 2
Recruiting
AMLM26/T2- INTERCEPT (Investigating Novel Therapy to Target Early Relapse and Clonal Evolution as Pre-emptive Therapy in Acute Myeloid Leukaemia (AML)): A Multi-arm, Precision-based, Recursive, Platform Trial - Ivosidenib + Venetoclax (
AMLM26-T2
)
Bcl2 inhibitor
IDH1 R132 inhibitor
Acute myeloid leukaemia
NSW
2050 - Camperdown - Chris O'Brien Lifehouse
2065 - St Leonards - Northern Sydney Cancer Centre, Royal North Shore Hospital
2139 - Concord - Concord Repatriation General Hospital
2145 - Westmead - The Crown Princess Mary Cancer Centre - Westmead Hospital
2298 - Waratah - Calvary Mater Newcastle Medical Oncology
VIC
3000 - Melbourne - Peter MacCallum Cancer Centre
3004 - Melbourne, Southbank - Alfred Health
3053 - Parkville - The Royal Women's Hospital and Institute of Maternal and Child Health
3168 - Clayton - Monash Medical Centre
3220 - Geelong - Andrew Love Cancer Centre, University Hospital Geelong
QLD
4006 - Herston - The Royal Brisbane and Women's Hospital Cancer Centre
4102 - Woolloongabba - Princess Alexandra Hospital
4215 - Southport - Gold Coast University Hospital
SA
5000 - Adelaide - Royal Adelaide Hospital - Adelaide Cancer Centre
WA
6009 - Nedlands - Sir Charles Gairdner Hospital - WA Cancer Centre
6150 - Murdoch - Fiona Stanley Hospital
ACTRN12624000110583
Advanced
Not Applicable
Recruiting
SOCRATES PILOT: Standard of Care Randomised Treatment Evaluation Studies (
SOCRATES-PILOT
)
AR-targeted agent,next generation
AR-targeted agent,second generation
Abiraterone
Anastrozole
Apalutamide
Atorvastatin
Bevacizumab
CYP17A1 inhibitor
Darolutamide
Enzalutamide
HMG-CoA reductase inhibitor
Letrozole
Lomustine
Nab-paclitaxel
Niraparib
Olaparib
PARP1/2 inhibitor
PARP inhibitor
Paclitaxel
alkylating agent
anti-VEGF monoclonal antibody
antiandrogen
antiandrogen,nonsteroidal
antiandrogen,nonsteroidal,second generation
aromatase inhibitor
cancer therapy
cancer therapy,AR-targeting
cancer therapy,CYP17A1-targeting
cancer therapy,HMG-CoA reductase-targeting
cancer therapy,PARP-targeting
cancer therapy,VEGF-targeting
cytotoxic chemotherapy
endocrine therapy
endocrine therapy,androgen axis-targeting
endocrine therapy,oestrogen axis-targeting
immuno-oncology therapy,VEGF-targeting
oestrogen receptor-targeting therapy
taxane
Cervical cancer
Glioblastoma
Ovarian cancer
Prostate cancer
NSW
2031 - Randwick - Prince of Wales Hospital
2050 - Camperdown - Chris O'Brien Lifehouse
2139 - Concord - Concord Repatriation General Hospital
ACTRN12624000082505
Haem
Phase 1 / Phase 2
Recruiting
AMLM26/T1- INTERCEPT (Investigating Novel Therapy to Target Early Relapse and Clonal Evolution as Pre- emptive Therapy in AML): A Multi-arm, Precision- based, Recursive, Platform Trial - Gilteritinib+ Venetoclax (
AMLM26-T1--INTERCEPT
)
AXL/FLT3 inhibitor
Bcl2 inhibitor
Acute myeloid leukaemia
NSW
2050 - Camperdown - Chris O'Brien Lifehouse
2065 - St Leonards - Northern Sydney Cancer Centre, Royal North Shore Hospital
2139 - Concord - Concord Repatriation General Hospital
2145 - Westmead - The Crown Princess Mary Cancer Centre - Westmead Hospital
2298 - Waratah - Calvary Mater Newcastle Medical Oncology
VIC
3000 - Melbourne - Peter MacCallum Cancer Centre
3053 - Parkville - The Royal Women's Hospital and Institute of Maternal and Child Health
3168 - Clayton - Monash Medical Centre
3220 - Geelong - Andrew Love Cancer Centre, University Hospital Geelong
QLD
4006 - Herston - The Royal Brisbane and Women's Hospital Cancer Centre
4102 - Woolloongabba - Princess Alexandra Hospital
4215 - Southport - Gold Coast University Hospital
SA
5000 - Adelaide - Royal Adelaide Hospital - Adelaide Cancer Centre
WA
6009 - Nedlands - Sir Charles Gairdner Hospital - WA Cancer Centre
6150 - Murdoch - Fiona Stanley Hospital
NZ
NZ.1023 - Grafton - Auckland City Hospital - Cancer & Blood Research
ACTRN12624000006549
Haem
Phase 1 / Phase 2
Recruiting
AMLM26/T3- INTERCEPT (Investigating Novel Therapy to Target Early Relapse and Clonal Evolution as Pre-emptive Therapy in Acute Myeloid Leukaemia (AML)): A Multi-arm, Precision-based, Recursive, Platform Trial - LDAC + Venetoclax (
AMLM26-T3-INTERCEPT
)
Bcl2 inhibitor
Acute myeloid leukaemia
NSW
2050 - Camperdown - Chris O'Brien Lifehouse
2065 - St Leonards - Northern Sydney Cancer Centre, Royal North Shore Hospital
2139 - Concord - Concord Repatriation General Hospital
2145 - Westmead - The Crown Princess Mary Cancer Centre - Westmead Hospital
2298 - Waratah - Calvary Mater Newcastle Medical Oncology
VIC
3000 - Melbourne - Peter MacCallum Cancer Centre
3053 - Parkville - The Royal Women's Hospital and Institute of Maternal and Child Health
3168 - Clayton - Monash Medical Centre
3220 - Geelong - Andrew Love Cancer Centre, University Hospital Geelong
QLD
4102 - Woolloongabba - Princess Alexandra Hospital
4215 - Southport - Gold Coast University Hospital
SA
5000 - Adelaide - Royal Adelaide Hospital - Adelaide Cancer Centre
WA
6009 - Nedlands - Sir Charles Gairdner Hospital - WA Cancer Centre
6150 - Murdoch - Fiona Stanley Hospital
ACTRN12622000582752
Haem
Phase 1 / Phase 2
Recruiting
AMLM26/T4- INTERCEPT (Investigating Novel Therapy to Target Early Relapse and Clonal Evolution as Pre-emptive Therapy in Acute Myeloid Leukaemia (AML)): A Multi-arm, Precision-based, Recursive, Platform Trial - SNDX5613 (
AMLM26-T4
)
Revumenib
cancer therapy
cancer therapy,KMT2A-targeting
cancer therapy,menin-MLL1-targeting
cancer therapy,menin-targeting
menin-MLL1 inhibitor
menin inhibitor
Acute myeloid leukaemia
NSW
2050 - Camperdown - Chris O'Brien Lifehouse
2065 - St Leonards - Northern Sydney Cancer Centre, Royal North Shore Hospital
2139 - Concord - Concord Repatriation General Hospital
2145 - Westmead - The Crown Princess Mary Cancer Centre - Westmead Hospital
2298 - Waratah - Calvary Mater Newcastle Medical Oncology
VIC
3004 - Melbourne, Southbank - Alfred Health
3053 - Parkville - The Royal Women's Hospital and Institute of Maternal and Child Health
3168 - Clayton - Monash Medical Centre
3220 - Geelong - Andrew Love Cancer Centre, University Hospital Geelong
QLD
4006 - Herston - The Royal Brisbane and Women's Hospital Cancer Centre
4102 - Woolloongabba - Princess Alexandra Hospital
4215 - Southport - Gold Coast University Hospital
SA
5000 - Adelaide - Royal Adelaide Hospital - Adelaide Cancer Centre
WA
6009 - Nedlands - Sir Charles Gairdner Hospital - WA Cancer Centre
6150 - Murdoch - Fiona Stanley Hospital
ACTRN12621001265864
Haem
Phase 1 / Phase 2
Recruiting
AMLM26/T5- INTERCEPT (Investigating Novel Therapy to Target Early Relapse and Clonal Evolution as Pre-emptive Therapy in Acute Myeloid Leukaemia (AML)): A Multi-arm, Precision-based, Recursive, Platform Trial - MBG453 OR MBG453 and Azacitidine (
AMLM26-T5
)
DNA methyltransferase inhibitor
anti-TIM3 monoclonal antibody
antimetabolite
Acute myeloid leukaemia
NSW
2050 - Camperdown - Chris O'Brien Lifehouse
2065 - St Leonards - Northern Sydney Cancer Centre, Royal North Shore Hospital
2139 - Concord - Concord Repatriation General Hospital
2145 - Westmead - The Crown Princess Mary Cancer Centre - Westmead Hospital
2298 - Waratah - Calvary Mater Newcastle Medical Oncology
VIC
3000 - Melbourne - Peter MacCallum Cancer Centre
3004 - Melbourne, Southbank - Alfred Health
3053 - Parkville - The Royal Women's Hospital and Institute of Maternal and Child Health
3168 - Clayton - Monash Medical Centre
3220 - Geelong - Andrew Love Cancer Centre, University Hospital Geelong
QLD
4102 - Woolloongabba - Princess Alexandra Hospital
4215 - Southport - Gold Coast University Hospital
SA
5000 - Adelaide - Royal Adelaide Hospital - Adelaide Cancer Centre
WA
6009 - Nedlands - Sir Charles Gairdner Hospital - WA Cancer Centre
6150 - Murdoch - Fiona Stanley Hospital
Additional search terms:
API and Webpage URLs:
Copy /Bookmark
Filters
Recruitment Status
Recruiting (24)
Not yet recruiting (3)
Recruitment Country and State
NSW (26)
VIC (21)
QLD (17)
WA (14)
SA (12)
NZ (5)
TAS (2)
ACT (1)
Phase
Phase 1 (3)
Phase 1 / Phase 2 (11)
Phase 2 (3)
Phase 3 (9)
Trial Type
Advanced (18)
Haem (8)
Curative (1)
Cancer Therapy Class
Bcl2
19%
ERBB2
15%
PD-1
15%
PD-1/PD-L1
15%
oestrogen axis
15%
EGFR
11%
VEGF
11%
ER
11%
KRAS
7%
CDK4
7%
AR
7%
CYP17A1
7%
androgen axis
7%
DNA methyltransferase
7%
CDK2
4%
PRMT5
4%
MET
4%
PD-L1
4%
TIGIT
4%
CDK4 selective
4%
B7H3
4%
SMO
4%
CDK6
4%
BCMA
4%
GPRC5D
4%
IDH1
4%
IDH1 R132
4%
HMG-CoA reductase
4%
PARP
4%
AXL
4%
FLT3
4%
KMT2A
4%
menin-MLL1
4%
menin
4%
TIM3
4%
Facility
2139 - Concord - Concord Repatriation General Hospital (27)
2050 - Camperdown - Chris O'Brien Lifehouse (12)
2298 - Waratah - Calvary Mater Newcastle Medical Oncology (12)
6009 - Nedlands - Sir Charles Gairdner Hospital - WA Cancer Centre (12)
4102 - Woolloongabba - Princess Alexandra Hospital (10)
3168 - Clayton - Monash Medical Centre (9)
3000 - Melbourne - Peter MacCallum Cancer Centre (8)
2145 - Westmead - The Crown Princess Mary Cancer Centre - Westmead Hospital (8)
3004 - Melbourne, Southbank - Alfred Health (8)
6150 - Murdoch - Fiona Stanley Hospital (8)
3220 - Geelong - Andrew Love Cancer Centre, University Hospital Geelong (8)
4215 - Southport - Gold Coast University Hospital (7)
2065 - St Leonards - Northern Sydney Cancer Centre, Royal North Shore Hospital (7)
5000 - Adelaide - Royal Adelaide Hospital - Adelaide Cancer Centre (7)
2109 - North Ryde - Macquarie University Hospital (6)
4006 - Herston - The Royal Brisbane and Women's Hospital Cancer Centre (6)
3053 - Parkville - The Royal Women's Hospital and Institute of Maternal and Child Health (6)
2148 - Blacktown - Blacktown Hospital, Blacktown Cancer and Haematology Centre (5)
3084 - Heidelberg - Austin Hospital Olivia Newton-John Cancer Centre (5)
NZ.1023 - Grafton - Auckland City Hospital - Cancer & Blood Research (4)
2031 - Randwick - Prince of Wales Hospital (3)
3128 - Box Hill - Box Hill Hospital - Eastern Health (3)
3066 - Epping - Northern Hospital (2)
5011 - Woodville South - The Queen Elizabeth Hospital (2)
7000 - Hobart - Royal Hobart Hospital (2)
3021 - St Albans - Western Health - Sunshine Hospital (2)
3065 - Fitzroy - St Vincent's Hospital Melbourne (2)
3199 - Frankston - Peninsula Health Frankston Hospital (2)
4556 - Buderim - Sunshine Coast Haematology and Oncology Clinic (2)
NZ.8011 - Christchurch - Canterbury District Health Board - Christchurch Hospital Cancer Centre (2)
4575 - Birtinya - Sunshine Coast University Hospital (2)
2485 - Tweed Heads - The Tweed Hospital (2)
5042 - Bedford Park - Flinders Medical Centre (2)
3199 - Frankston - PASO Medical (1)
5000 - Adelaide - Cancer Research SA (1)
5065 - Toorak Gardens - Burnside War Memorial Hospital (1)
3084 - Heidelberg - Warringal Private Hospital (1)
2250 - Gosford - Central Coast Cancer Centre, Gosford Hospital (1)
2560 - Campbelltown - GenesisCare Campbelltown (1)
4032 - Chermside - The Prince Charles Hospital (1)
2605 - Garran - The Canberra Hospital (1)
4350 - Toowoomba - Toowoomba Hospital (1)
2576 - Bowral - Southern Highlands Private Hospital (1)
4814 - Douglas - Townsville Cancer Centre - The Townsville Hospital (1)
5000 - South Australia - GenesisCare St Andrews Hospital (1)
2031 - Randwick - Scientia Clinical Research Ltd (1)
2228 - Miranda - Southside Cancer Care Centre (1)
2305 - New Lambton Heights - John Hunter Children's Hospital (1)
4224 - Tugun - Genesis Care Tugun - John Flynn Private Hospital (1)
6009 - Nedlands - Linear Clinical Research (1)
3355 - Wendouree - Ballarat Oncology & Haematology Clinical Trials Unit (1)
4101 - South Brisbane - Mater Hospital Brisbane / ICON Cancer Centre (1)
2217 - Kogarah - St George Hospital (1)
2800 - Orange - Orange Hospital-Cancer Centre Clinical Trials Unit (1)
6009 - Nedlands - One Clinical Research (1)
NZ.0622 - Takapuna - North Shore Hospital (1)
NZ.6021 - Wellington - Capital & Coast District Health Board - Wellington Hospital (1)
2076 - Wahroonga - Sydney Adventist Hospital (1)
2747 - Kingswood - Nepean Hospital - Nepean Cancer Care Centre (1)
3002 - Melbourne - Peter MacCallum Cancer Centre, East Melbourne campus (1)
3690 - Wodonga - Border Medical Oncology at Wodonga Regional Cancer Centre (1)
4101 - South Brisbane - Queensland Children's Hospital (1)
NZ.1023 - Grafton - Starship Children's Hospital (1)
NZ.4442 - Roslyn - Palmerston North Hospital Cancer Centre - Palmerston North Hospital (1)
NZ.9016 - Dunedin - Dunedin Hospital (1)
2170 - Liverpool - Liverpool Hospital (1)
2060 - North Sydney - Mater Hospital (1)
3002 - East Melbourne - Epworth Freemasons (1)
3677 - Wangaratta - Northeast Health Wangaratta (1)
Cancer Type
Cancer
Solid tumour
Haematological malignancy
Leukaemia
Acute myeloid leukaemia
Myeloid leukaemia
Gastrointestinal cancer
Thoracic cancer
Upper gastrointestinal cancer
Lung cancer
Non-small cell lung cancer
Respiratory tract cancer
Breast cancer
Pancreatobiliary cancer
Urogenital cancer
Exocrine pancreatic cancer
Pancreatic adenocarcinoma
Pancreatic cancer
Gynaecological cancer
Ovarian cancer
Gastric cancer
Gastric carcinoma
Gastroesophageal cancer
Gastroesophageal junction adenocarcinoma
Oesophageal cancer
Male genital cancers
Prostate cancer
Multiple myeloma
Plasma cell disorder
Colorectal adenocarcinoma
Colorectal cancer
Lower gastrointestinal cancer
Gastric adenocarcinoma
HER2-positive gastric cancer
Biliary tract cancer
Hepatobiliary cancer
Breast adenocarcinoma
HER2-negative breast cancer
HR-positive breast cancer
Myelodysplastic syndrome
Myelodysplastic/Myeloproliferative disease
Myeloproliferative neoplasm
Germ cell tumour
Central nervous system cancer
Cervical cancer
Glioblastoma
Glioma
HPV-related cancer
HPV16-positive cancer
High-grade glioma
Malignant glioma
Neurological cancer
Viral-related cancer
URLs for this search
API URL:
Copy
Bookmarkable URL:
Copy